Results 231 to 240 of about 79,794 (267)

Structure of Eukaryotic Type I DNA Topoisomerase

1994
T, Hsieh, M P, Lee, S D, Brown
openaire   +2 more sources

Health insurance status and cancer stage at diagnosis and survival in the United States

Ca-A Cancer Journal for Clinicians, 2022
Jingxuan Zhao, Xuesong Han, Leticia M Nogueira   +2 more
exaly  

7 Mechanistic Aspects of Type-II DNA Topoisomerases

, 1990
T. Hsieh
semanticscholar   +1 more source

DNA topoisomerases I & II cleavage sites in the type 1 human immunodeficiency virus (HIV-1) DNA promoter region.

Biochemical and Biophysical Research Communications - BBRC, 1994
Y. Pommier, B. Poddevin, M. Gupta, J. Jenkins   +3 more
semanticscholar   +1 more source

An overview of precision oncology basket and umbrella trials for clinicians

Ca-A Cancer Journal for Clinicians, 2020
Kristian Thorlund, Edward J Mills
exaly  

Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.

Infectious Diseases - Drug Targets, 2007
Y. Tse‐Dinh
semanticscholar   +1 more source

DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.

Biochemistry, 1999
J. A. Byl, J. Fortune, D. Burden, J. Nitiss, T. Utsugi, Y. Yamada, N. Osheroff   +6 more
semanticscholar   +1 more source

Human DNA-Topoisomerases – Diagnostic and Therapeutic Implications for Cancer

Oncology Research and Treatment, 2000
U. Kellner, P. Rudolph, R. Parwaresch
semanticscholar   +1 more source

Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro.

Mutagenesis, 1990
L. Backer, J. Allen, K. Harrington‐Brock, J. Campbell, D. DeMarini, C. Doerr, D. R. Howard, A. Kligerman, M. Moore   +8 more
semanticscholar   +1 more source

Cancer statistics, 2017

Ca-A Cancer Journal for Clinicians, 2017
Rebecca L Siegel, Kimberly D Miller
exaly